Tepotinib
- Generic Name
- Tepotinib
- Brand Names
- Tepmetko
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28N6O2
- CAS Number
- 1100598-32-0
- Unique Ingredient Identifier
- 1IJV77EI07
- Background
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell lung cancer, and hepatocel...
- Indication
Tepotinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
- Conditions
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 88
- Registration Number
- NCT01982955
- Locations
- 🇨🇳
Jilin University, Changchun, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.